I have a recollection (possibly from something NP said a couple of weeks ago) that the FDA might agree to to view the results of both trials on a cumulative basis in order to offset the intrinsically low power of each small sample size.

I don't know if NP was just shooting from the hip, but does anyone else remember this happening?

If that memory is correct, I wonder if there is a plan for CytoDyn / Amarex to process the results from both trials as they become available -- but present them to the FDA at the same exact time.

And that causes me to wonder if the FDA will issue the equivalent of a non-disclosure order, preventing NP from announcing the preliminary results from the first available trial (P3 S/C) to investors.

Happy to get input from the board on this.